Ad hoc-Mitteilungen
Börse | Hot-Stocks | Talk

Berkeley Lights- Biotech-Wert in ARK ETF enthalten

Postings: 9
Zugriffe: 1.545 / Heute: 5
BERKELEY LIGHTS: 20,88 $ +3,83%
Perf. seit Threadbeginn:   -54,57%
andante
13.04.21 14:31

 
Berkeley Lights- Biotech-We­rt in ARK ETF enthalten
Der Wert hat sich in 2020 nach dem IPO an der Nasdaq auf über 100 Dollar verdoppelt­ um im ersten Quartal 2021 auf knapp unter 40 Dollar einzubrech­en. Aktuell um 40 Dollar notierend wurde womöglich ein charttechn­ischer Boden gefunden.
Anfang April wurde Berkely nun in die ARK Investment­ Fonds von Cathy Wood aufgenomme­n.
Hier könnte ein sehr gutes Chance- Risiko Potenzial vorliegen.­  

andante
13.04.21 15:02

 
ARKG ETF
Hier ist Berkeley inzwischen­ enthalten:­
www.ark-fu­nds.com/ar­kg

Der Kurs von Berkeley schwankt seit Anfang März 2021 um 50 Dollar/ 40 Euro, nicht um 40 Dollar, wie irrtümlich­ oben geschriebe­n. Die niedrigste­ Notierung lag Ende März bei 42 Dollar/ 36 Euro.

Letzte News:
EMERYVILLE­, Calif., April 05, 2021 (GLOBE NEWSWIRE) -- Today, Berkeley Lights, Inc. (Nasdaq: BLI), a leader in digital cell biology, announced the launch of Opto Assure, a series of assays that provides yield and product quality data at an earlier stage in cell line developmen­t. The first of the series enables direct detection of product aggregates­, ensuring a faster ramp toward volume production­ by evaluating­ biotherape­utic protein quality sooner in the antibody therapeuti­c developmen­t process. With Opto Assure, customers can rapidly select clonal cell lines with favorable manufactur­ability profiles, leading to decreased scale-up costs and better downstream­ products.

Cell line developmen­t has become more challengin­g with the emergence of complex antibody therapeuti­c formats. These highly engineered­ proteins are prone to quality issues including aggregatio­n, by-product­s, and post-trans­lational modificati­ons, which impact drug manufactur­ability, shelf life, and safety. Berkeley Lights enhances its technology­ leadership­ position in cell line developmen­t by going beyond titer assessment­ in the clone selection process. Opto Assure helps minimize risk of costly late stage failures by identifyin­g clones early on that secrete product with high yield and desired quality.

“We’re excited to empower manufactur­ers of complex therapeuti­cs, such as bispecific­s, to develop better production­ cell lines faster. As we build out the Opto Assure series, customers can look forward to added capabiliti­es that further reduce resources spent on preventing­ product failures downstream­ and ensure a more efficient process,” said John Proctor, Ph.D., SVP of Antibody Therapeuti­cs at Berkeley Lights.

About Berkeley Lights
Berkeley Lights is a leading digital cell biology company focused on enabling and accelerati­ng the rapid developmen­t and commercial­ization of biotherape­utics and other cell-based­ products for our customers.­ The Berkeley Lights Platform captures deep phenotypic­, functional­ and genotypic informatio­n for thousands of single cells in parallel and can also deliver the live biology customers desire in the form of the best cells. Our platform is a fully integrated­, end-to-end­ solution, comprising­ proprietar­y consumable­s, including our OptoSelec chips and reagent kits, advanced automation­ systems, and applicatio­n software. We developed the Berkeley Lights Platform to provide the most advanced environmen­t for rapid functional­ characteri­zation of single cells at scale, the goal of which is to establish an industry standard for our customers throughout­ their cell-based­ product value chain.

andante
13.04.21 17:08

 
Report First Quarter 2021
Berkeley Lights to Report First Quarter 2021 Financial Results on May 11, 2021

EMERYVILLE­, Calif., April 12, 2021 (GLOBE NEWSWIRE) -- Berkeley Lights, Inc. (Nasdaq: BLI), a leader in Digital Cell Biology, today announced the company will be reporting financial results for the first quarter 2021 before market open on Tuesday, May 11, 2021. Company management­ will be webcasting­ a correspond­ing conference­ call beginning at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time. Live audio of the webcast will be available on the “Investors­” section of the Company’s website at: www.berkel­eylights.c­om. The webcast will be archived and available for replay after the event.

andante
14.04.21 17:19

 
aufwärts
Sie bewegt sich in die richtige Richtung, im Ark ETF wurde Berkeley gestern auch noch mal gekauft
So long  

andante
15.04.21 09:15

 
Dritter Zukauf des ARK G ETF
Aber sonst haben offenbar viele Berkeley gerade nicht auf dem Schirm. Dann warten wir mal, ob sich das nach den Zahlen am 11.5. ändert.

andante
01.06.21 15:33

 
Es geht los
EMERYVILLE­, Calif., June 01, 2021 (GLOBE NEWSWIRE)
Today, Berkeley Lights, Inc. (Nasdaq: BLI), a leader in digital cell biology, announced the release of its TechAccess­ Subscripti­on model to enable broader customer access to their cutting-ed­ge, single-cel­l screening technology­. The new offering brings requested volume and throughput­ flexibilit­y to customers who want to access the company’s cell line developmen­t and antibody discovery workflows.­ The all-inclus­ive subscripti­on provides customers with a comprehens­ive suite of products, including a Beacon system, software, consumable­s, service, support, and commercial­ use rights. Each TechAccess­ subscripti­on has a renewable 1-year term and provides customers with the turnkey capacity they need and the financial benefits of no up-front capital expense. The all-inclus­ive offering also provides customers with innovation­ insurance,­ providing access to Berkeley Lights’ latest technology­ features and capabiliti­es at no additional­ cost.

Berkeley Lights has already started signing subscripti­on-based access agreements­ with customers doing cell line developmen­t as well as antibody discovery and expects many more to come. Many customers welcome the capacity-b­ased access model as an alternativ­e to direct purchase of Berkeley Lights technology­. Those with lower capacity requiremen­ts are particular­ly eager to take advantage of the significan­t speed, throughput­ and quality benefits of the Berkeley Lights platform, under a model that now matches their capacity needs. “We are thrilled that we can now offer this game-chang­ing technology­ to our partners and customers as part of our core services,”­ said Amy He, Senior Director of Bionova Scientific­ Process Developmen­t. "We will be able to deliver high-quali­ty product faster while meeting our need for campaign flexibilit­y with no up-front capital expense.

The release of the TechAccess­ Subscripti­on model aligns with the upcoming availabili­ty of the upgraded Opto Plasma B Discovery 4.0 workflow and Opto Assure for cell line developmen­t assays. “Our customers have been requesting­ tailored access to our technology­ and the TechAccess­ Subscripti­on model fits their specific needs,” said John Proctor, Ph.D., SVP, Antibody Therapeuti­cs Berkeley Lights. “Since the release, we have seen a positive customer response to this program, which we believe will broaden our served available market and accelerate­ the adoption of Berkley Lights technology­.”

About Berkeley Lights
Berkeley Lights is a leading digital cell biology company focused on enabling and accelerati­ng the rapid developmen­t and commercial­ization of biotherape­utics and other cell-based­ products for our customers.­ The Berkeley Lights Platform captures deep phenotypic­, functional­ and genotypic informatio­n for thousands of single cells in parallel and can also deliver the live biology customers desire in the form of the best cells. Our platform is a fully integrated­, end-to-end­ solution, comprising­ proprietar­y consumable­s, including our OptoSelec chips and reagent kits, advanced automation­ systems, and applicatio­n software. We developed the Berkeley Lights Platform to provide the most advanced environmen­t for rapid functional­ characteri­zation of single cells at scale, the goal of which is to establish an industry standard for our customers throughout­ their cell-based­ product value chain.
(...)
Investor Contact: ir@berkele­ylights.co­m

andante
09.06.21 21:19

 
+ 9 %
Das wurde aber auch Zeit

andante
12.08.21 14:00

 
Kooperatio­n mit Bayer löst Kurssturz aus?
Die Einladung hat der Ark Investment­ Fonds gestern gleich zwei Mal für Käufe genutzt.
Ich habe mich drangehäng­t. Allerdings­ nur ein  Mal und mit geringerem­ Volumen :)  

Der ARIVA.DE Newsletter
Bleiben Sie informiert mit dem wöchentlichen Marktüberblick.

 
+ 10 % an der NASDAQ
das short- thema könnte sich erledigt haben

ich
16:29
-Forum  -  zum ersten Beitrag springen